摘要
Dear Editor,Since September 2012, the Middle East respiratory syndrome coronavirus (MERS-CoV) cases have been reported in more than 27 countries, and more than 2,000 cases have been confirmed in the laboratory (http://www.who.int/emergencies/mers-cov/en/). MERS-CoV causes an acute and severe respiratory illness with a high mortality rate(~35%) in humans (Shi et al., 2017, Zaki et al., 2012).Neutralizing antibodies targeting the spike of MERS-CoV have been shown to be a therapeutic option for treatment of lethal disease (Agrawal et al., 2016, Ying et al., 2014).
Dear Editor,Since September 2012, the Middle East respiratory syndrome coronavirus （MERS-CoV） cases have been reported in more than 27 countries, and more than 2,000 cases have been confirmed in the laboratory （http：//www.who.int/emergencies/mers-cov/en/）. MERS-CoV causes an acute and severe respiratory illness with a high mortality rate（-35%） in humans （Shi et al., 2017, Zaki et al., 2012）.Neutralizing antibodies targeting the spike of MERS-CoV have been shown to be a therapeutic option for treatment of lethal disease （Agrawal et al., 2016, Ying et al., 2014）.
基金
supported by the National Key Research and Development Program of China (2016YFD0500300 to Wenjie Tan)
